-
WinHealth Pharma Receives NMPA Approval for Glycerol Phenylbutyrate for Urea Cycle Disorders
•
China-based Hong Kong WinHealth Pharma Group Ltd has announced receiving market approval from the National Medical Products Administration (NMPA) for its glycerol phenylbutyrate, a drug used as a long-term treatment for patients with urea cycle disorders (UCDs). This approval specifically targets patients who cannot achieve disease control through protein intake…
-
Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial
•
China-based Nanjing Leads Biolabs Co., Ltd has revealed that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to initiate a Phase I/II clinical trial for its pipeline candidate, LBL-033. This anti-MUC16/CD3 bispecific antibody (BsAb) is set to be investigated as a potential…
-
AstraZeneca Weighs Spinning Off China Business to Shield Against Geopolitical Tensions
•
According to a report from the UK newspaper The Financial Times (FT), AstraZeneca (AZ, NASDAQ: AZN) has drafted plans to spin off its China business as a separate entity. Citing “three people familiar with the talks,” the UK-based pharmaceutical giant is said to have begun discussing the idea with bankers…
-
TG ImmunoPharma Receives FDA Approval for Phase I Clinical Study of TGI-6 Bispecific Antibody
•
China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its bispecific antibody (BsAb), TGI-6. This development marks a significant step forward in the company’s efforts to bring innovative immunotherapies to patients…
-
IASO Bio Receives FDA IND Approval for IASO-782 for Autoimmune Disorders
•
China-based IASO Bio has announced that the US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) filing for its pipeline candidate, IASO-782. This injectable drug candidate will be assessed in US clinical trials for the treatment of various autoimmune hematological disorders, including primary immune thrombocytopenia (ITP)…
-
Adicon Holdings Ltd IPO: A Strategic Move for Growth in Diagnostics
•
Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully completed its initial public offering (IPO) of 33.2 million shares on the Hong Kong Stock Exchange. The shares were priced at HKD 12.32 (USD 1.58) each, with net proceeds expected to reach HKD 83.9 million…
-
Acotec Scientific Holdings and Boston Scientific Group plc Sign MOU to Broaden Collaboration
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a memorandum of understanding (MoU) with US firm Boston Scientific Group plc (BSG, NYSE: BSX), signaling their intention to explore collaboration in multiple fields, including research and development (R&D), manufacturing, and marketing and sales. Financial details of the agreement were not…
-
Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase I/II study for its Category 1 biologic product candidate ASKB589, which is being assessed as a treatment for solid tumors. The findings were presented at the 15th International Gastric Cancer Association (IGCA) meeting, highlighting the…
